Clinical Research Directory
Browse clinical research sites, groups, and studies.
Genomics and COVID-19 Vaccine Adverse Events
Sponsor: University of British Columbia
Summary
Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events. The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).
Official title: Genomics of COVID-19 Vaccine-induced Adverse Events (Guillain-Barré Syndrome [GBS], Vaccine-induced Immune Thrombotic Thrombocytopenia [VITT]/thrombosis with Thrombocytopenia Syndrome [TTS], and Myocarditis/pericarditis)
Key Details
Gender
All
Age Range
5 Years - 99 Years
Study Type
OBSERVATIONAL
Enrollment
6325
Start Date
2022-06-24
Completion Date
2025-12
Last Updated
2024-12-05
Healthy Volunteers
Yes
Conditions
Interventions
COVID-19 vaccines
Any licensing COVID-19 vaccine platform
Locations (1)
British Columbia Children's Hospital Research Institute
Vancouver, British Columbia, Canada